TOP - August 2017, Vol 10, No 3
Although the 5-year survival rate for multiple myeloma is less than 50%, this type of cancer has witnessed a resurgence of drug therapies.
Each year, >200,000 individuals in the United States are diagnosed with a primary or metastatic brain tumor. Primary brain tumors comprise approximately 40,000 of these diagnoses.
Here's what you can expect to find in the August issue of The Oncology Pharmacist.
By Chase Doyle
The United States may be in the midst of an opioid epidemic, but the undertreatment of pain remains an issue for patients with cancer.
By Chase Doyle
Childhood cancer therapy can be a double-edged sword; it often leads to a cure, but long after treatment ends, some survivors have treatment-related side effects.
By Chase Doyle
The power to fight a virtually infinite array of pathogens is one of the hallmarks of the human immune system, and random diversity is its secret weapon.
By Phoebe Starr
Adding the investigational drug indoximod, an indoleamine 2,3-dioxygenase (IDO) pathway inhibitor, to the checkpoint inhibitor pembrolizumab led to higher response rates in patients with advanced melanoma than what is reported with pembrolizumab monotherapy,
By Chase Doyle
Although transplantation offers cures or durable remissions for malignancies, relapse is a frequent occurrence in many diseases, and remains a major cause of mortality.
By Chase Doyle
Despite significant progress in stem-cell transplantations over the past decade, graft-versus-host disease (GVHD) remains the leading cause of nonrelapse death in this patient population.
By Chase Doyle
Precision medicine continues to transform oncology, and it is not just the treatments that are changing.